Molecular structure and supramolecular assembly of a TGF-β1 mimetic oligopeptide

DNA-templated self-assembly of bradykinin into bioactive nanofibrils

“…We selected this concentration range because it covers the critical concentration values commonly observed for short peptides that share physicochemical similarities with BK. 24,26,33 In addition, we conducted experiments with BK-DNA complexes in the presence of other fluorophores, keeping the DNA concentration constant at 60 mM and titrating BK. Intensities have been normalized to the emission of the DNA solution (without peptide) and the fluorescence of the solution containing only the fluorophore was taken as the background threshold.…”

“…values. This procedure is widely used in the study of peptide self-assembly, 16,17,24,26,33 and by estimating C.A.C. values of BK solutions in the presence or absence of DNA, we can compare the aggregation behavior of the peptide and gain insights into the role of DNA as a mediator of aggregation.…”

Supramolecular Motion Enables Chondrogenic Bioactivity of a Cyclic Peptide Mimetic of Transforming Growth Factor-β1

“…The therapeutic potential of TGF-β1 for cartilage repair has been demonstrated extensively, including in intraarticular injections, , growth factor-loaded scaffolds, , and growth factor-binding scaffolds. , However, the impact of TGF-β1 signaling on cellular structure and function is highly context-dependent and can include deleterious effects including inflammation, − fibrosis, ,− and OA. ,, Current preclinical biomaterials-based strategies for cartilage repair rely on the addition of exogenous TGF-β1, − and clinical trials have focused on direct injections of the protein. , Treatments using exogenous protein pose potential problems due to their short half-life, low stability, and potential to diffuse uncontrollably from the delivery site, resulting in off-target effects. , It has been reported that the peptide CESPLKRQC, discovered via phage display, binds to the type II TGF-β receptor with high affinity − Considering the lack of small molecule drugs to treat cartilage degeneration and the poor stability and imprecise spatiotemporal control in exogenous growth factor delivery, synthetic systems containing functional peptides are promising therapies that can serve as both structural scaffolds and bioactive signals …”